Gocovri (amantadine) extended-release capsules are used for treatment of dyskinesia (involuntary movement disorders) in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications.

Dyskinesia is often a side effect of levodopa-based Parkinson's disease treatment. Approved in August 2017, Gocovri is the first medicine for the treatment of dyskinesia in Parkinson's disease patients.

In 2021, the US Food and Drug Administration (FDA) also expanded the approval of Gocovri to include the treatment of "off" episodes in Parkinson's disease patients taking levodopa/carbidopa. "Off" episodes occur when symptoms return because the medication is not working well.

Parkinson's disease is a progressive nervous system disorder affecting movement.